1Straume O,Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low- grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 2003,9(1) :250.
2Makinen T, Jussila L, Veikkola T et al . Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor- 3.Nat Med. 2001,7(2):199.
3Stefano J,Mandriota,lotta et al . Vascular endothelial growth factor- c - mediated lymphangiogenesis promotes tumour metastasis. EMBOJ. 2001,20(4) :672.
4Tanja Veikkola,lotta Jussila,Taija Makinen et al . Signalling via vascular endothelial growth factor receptor- 3 is sufficient for lymphangiogenesis in transgenic mice. EMBOJ. 2001, 20(6):1223.
5Pepper MS, Tille JC, Nisato R et al . Lymphangiogenesis and tumor metastasis. Cell Tissue Res,2003,314:167.
6Stacker SA, Williams RA,Achen MG. Lymphangiogenic growth factors as markers of tumor metastasis. APMIS,2004,112:539.
7Krishnan J, Kirkin V, Steffen A et al . Differential in vivo and in vitro expression of vaseular endothelial growth factor VEGF - C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 2003,63 (3) : 713.
8Aprelikova O, Pajusola K, Partanen J et al . FLT4, a novel class Ⅲ receptor tyrosine kinase in chromosome 5q33 - qter. Cancer Res, 1992,52:746.
9IIjin K, Karkkainen M J, Lawrence EC et al . VEGFR3 gene slrueture, regulatory, legion and sequence polymorphisms. FASEB J. 2001, 15 (6) : 1028.
10Nakamura Y, Yasuoka H, Tsujimoto M et al . Flt - 4 positive vessel density correlates with vascular endothelial growth factor- d expression, nodal states and prognosis in breast cancer. Clin Cancer Res. 2003,9(14) :5313.
二级参考文献35
1[1]Pepper MS. Lymphangiogenesis and tumor metastasis: mythos or reality[J]. Clin. Cancer Res, 2001,7:462-468.
2[2]Fisher B. Role of the lymphatic system in dissemination of tumor,in lymph and the lymphatic system led [M]. Mayerson. H.S.324(Charles C. Thomas. Springfield, Illinois.1968).?
3[3]Skobe M. Structure function and molecular control of the skin lymphatic system.[J]. J.Invest. Dermatol. Symp. Proceed, 2000, 5:14-19.
4[4]Partanen TA. Lack of lymphatic vascular specificity of vascular endothelial growth factor erceeptor 3 in 185 vascular tumors[J].Cancer, 1999,86:2406-2412.
5[5]Valtola R. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer [J]. Am J.Pathol, 1999,154:1381-1390.
6[6]Banerji S. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan[J]. J. Cell Biol, 1999,144:789-801.
7[7]Prevo R. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium[M]. J.Biol. Chem,2001:19420-19430.
8[8]Gale NW and Yancopoulos GD. Growth factors acting via endothelial venules cell-specific receptor tyrosine kinases:VEGFs,angiopoietins and ephrins in vascular development [J].Genes Dev,1999,13:1055-1066.
9[9]Lee FC, Tilghmann RC. Lymph vessels in rabbit carcinoma, with a note on the normal lymph vessel structure of the testis [J].Arch Surg, 1993,26:602-616.
10[10]Gilchrist RK. Surgical management of advanced cancer of the breast [J].Arch.Surg, 1950,61:913-929.
